[2] Giroir starting in 2016 served as president and CEO of ViraCyte, LLC, a clinical-stage biopharmaceutical company focused on discovering and developing cellular immunotherapies for severe infections.

He was a member of the Texas Task Force for Infectious Disease Preparedness and Response, and an adjunct professor of pediatrics at the Baylor College of Medicine in Houston.

[3] Giroir served as the Acting Commissioner of Food and Drugs in November and December 2019, while Stephen Hahn's nomination was pending in the Senate.

Giroir graduated from all-male Catholic Jesuit High School in New Orleans, Louisiana,[4] where he was also served as a drill team commander in the U.S. Marine Corps JROTC.

Giroir has published over 85 academic articles, chapters, and books on a variety of topics including host-pathogen interactions and novel therapies for life-threatening infectious diseases.

Giroir's focus was leading the development of the biotechnology initiatives within the Texas A&M University System and the Biocorridor in Brazos County.

"[27][28][29][30] Robin Robinson, who was the director of the federal Biomedical Advanced Research and Development Authority and oversaw a major grant for the Texas vaccine project, said Giroir "over-promised and under-delivered.

[33] Starting in November 2016, Giroir served as president and CEO of ViraCyte, LLC, a clinical-stage biopharmaceutical company focused on discovering and developing cellular immunotherapies for severe infections.

[42] In April 2018, Senator Ron Wyden (D-Oregon) criticized Giroir for neglecting to address the role of drug companies in sparking the opioid crisis.

[43] In September 2018, Senator Claire McCaskill (D-Missouri) wrote to Health Secretary Alex Azar: "At a hearing of the Senate Committee on Finance in April 2018, I asked Admiral Brett P. Giroir ... whether HHS had demanded explanations from pharmaceutical manufacturers that had raised prices for the opioid-reversal drug naloxone.

Admiral Giroir stated he had not asked the companies to explain their dramatic price increases, but promised he would 'get back to [me] on whether [he] could write a letter.'

[48][49][50] Senator Patty Murray (D-Washington) said that she was "alarmed" by Giroir's "track record of letting ideology drive decisions at the expense of women and families.

[52][53] On 15 November 2018, president Trump nominated Giroir to serve the additional role of representative of the United States on the executive board of the World Health Organization.

[59][60] Giroir served on the scientific advisory boards of the Cancer Moonshots Program at MD Anderson Cancer Center, the A. Alfred Taubman Medical Research Institute at the University of Michigan, the Institute for Patient Safety at the University of North Texas Health Science Center, and was a member of the board of directors of Esperance Pharmaceuticals[61] and BioHouston.

The Governor named Giroir as director of the task force to lead a team of experts in epidemiology and infectious disease.